Browse > Article

Construction of Recombinant BCGs Overexpressing Antigen 85 Complex and Their Protective Efficacy against Mycobacterium tuberculosis Infection in a Mouse Model  

Lee, Seung-Heon (Department of Molecular Biology, Korean Institute of Tuberculosis)
Jeon, Bo-Young (Department of Microbiology, Yonsei University College of Medicine)
Park, Young-Gil (Department of Molecular Biology, Korean Institute of Tuberculosis)
Lee, Hye-Young (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Cho, Sang-Nae (Department of Microbiology, Yonsei University College of Medicine)
Kim, Hyo-Joon (Department of Biochemistry and Molecular Biology, College of Science Technology, Hanyang University)
Bai, Gill-Han (Department of Molecular Biology, Korean Institute of Tuberculosis)
Publication Information
Tuberculosis and Respiratory Diseases / v.57, no.2, 2004 , pp. 125-131 More about this Journal
Abstract
Tuberculosis (TB) remains an enormous global health problem, and a new vaccine against TB more potent than the current inadequate BCG vaccine is urgently needed. We constructed three recombinant Mycobacterium bovis BCG (rBCG) strains over-expressing antigen (Ag) 85A, Ag85B, or both of M. tuberculosis using their own promoter and secretory sequence, or hsp60 promoter. SDS-PAGE analysis of rBCG proteins showed overexpression of Ag85A and Ag85B proteins in higher level than of those in their parental strain of BCG. In addition, rBCG(rBCG/B.FA) over-expressing Ag85A and Ag85B induced strong IFN-${\gamma}$ production in splenocytes. However, there was no significant difference in protective efficacy between rBCG and their parental BCG strain. In this study, therefore, rBCG over-expressing Ag85A, Ag85B, or both failed to show enhanced protection against M. tuberculosis infection in a mouse model.
Keywords
Tuberculosis; Vaccine; Recombinant BCG;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45
2 Horwitz MA, Lee BW, Dillon BJ, Horth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1995;92:1530-4
3 Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000;68: 791-5
4 Weinrich Oslen A, van Pinxteren LA Mang Okkels L, Rasmussen P, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and east-6. Infect Immun 2001;69:2773-8
5 Wiker HG, Harboe, M. The antigen 85 complex: A major secretion product of Mycobacterium tuberculosis. Microbiol. Rev. 1992;56:648-61
6 Ohara N, Matsuoka M, Nomaguchi H, Naito M, Yamada T. Inhibition of multiplication of Mycobacterium leprae in mouse foot pads by recombinant Bacillus Catmette-Guerin(BCG). Vaccine 2000;18: 1294-7
7 Ting LM, Kim AC, Cattamanchi A, Ernst JD. Mycobacterium tuberculosis inhibits IFN-gamma transcriptional responses without inhibiting activation of STAT1. J Immunol 1999;163:3898-906
8 Bao L, Chen W, Zhang H, Wang X. Virulence, immunogenicity, and protective efficacy of two recombinant Mycobacterium bovis bacillus Calmette- Guérin strains expressing the antigen ESAT-6 from Mycobacterium tuberculosis. Infect Immun 2003;71: 1656-61
9 Murray PJ, Aldovani A, Young RA. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc Natl Acad Sci USA 1996;93:934-9
10 Lalvani A, Brookes R, Wilkinson RJ, Malin AS, Pathan AA, Andersen P, et al. Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1998;95:270-5
11 Ellner JJ, Hirsch CS, Whalen CC. Correlates of protective immunity to Mycobacterium tuberculosis in humans. Clin Infect Dis 2000;30(Suppl.3):S279-82
12 Guleria I, Teitelbaum R, McAdam RA, Kalpana G, Jacobs WR Jr, Bloom BR. Auxotrophic vaccines for tuberculosis. Nat Med 1996;2:334-7
13 Launois P, Niang MN, De Bruyn JD, Sarthou JL, Rivier F, Drowart A, et al. The major secreted antigen complex(Ag85) from Mycobacterium bovis bacile Calmette- Guérin is associated with protective T cells in leprosy: A follow-up study of 45 household contacts. J Infect Dis 1993;167:1160-7
14 Launois P, Deleys R, Niang MN, Drowart A, Andrien M, Dierckx P, et al. T cell epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect Immun 1994;62: 3679-87
15 Lee HY, Cho SN, Kim HJ and Kim JD. Construction of a Mycobacterium- cherichia coli shuttle vector and use in the expression of foreign genes in Mycobacteria. The Journal of the Korean Society for Microbiology 1997;32:292-300
16 Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1994;62:2536-44
17 Orme IM, Miller E, Roberts AD, Furney SK, Griffin JP, Dobos KM, et al. T Lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection. J Immunol 1992;148:189-96
18 Zhang M, Lin Y, lyer DV, Gong J, Abrams JS, Barnes PF. T cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect Immun 1995;63:3231-4
19 Aldwell FE, Keen DL, Parlane NA, Skinner MA, de Lisle GW, Buddle BM. Oral vaccination with Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in brushtail possums. Vaccine 2003;22:70-6
20 Kumar P, Amara RR, Challu VK, Chadda VK, Satchidanandam V. The Apa protein of Mycobacterium tuberculosis stimulates gamma interferonsecreting CD4+ and CD8+ T cells from purified protein derivative-positive individuals and affords protection in a guinea pig model. Infect Immun 2003;71:1927-37
21 Centers for Disease Control and Prevention: Development of new vaccines for tuberculosis. Recommendations of the Advisory Council for the Elimination of Tuberculosis(ACET). MMWR Recomm Rep. 1998;47:1-6
22 Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, et al. Immunogenicity and protective efficacy of a tuber culosis DNA vaccine. Nat Med 1996;2:893-8
23 Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus Calmette Guérin(BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000;97:13853-8
24 Orme IM, Roberts AD, Griffin JP, Abrams JS. Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J Immunol 1993;151:518-25
25 Ohara N, Matsuoka M, Nomaguchi H, Naito M, Yamada T. Protective responses against experimental Mycobacterium leprae infection in mice induced by recombinant bacillus Calmette-Guérin over-producing three putative protective antigen candidates. Vaccine 2001;19:1906-10